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MCI patients from controls was significantly (p  ! 0.05) supe-
rior to that of FDG-PET (75 vs. 44%) at a comparably high 
specificity (82 vs. 91%); t-tau measures were less accurate in 
all analyses.  Conclusions: FDG-PET and CSF p-tau 181 levels 
are able to discriminate DAT in heterogeneous and unse-
lected samples with a high accuracy. CSF p-tau 181 might
be somewhat superior for a sensitive detection of patients 
with MCI.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Tauopathy and loss of synaptic activity/density are 
major early events in the pathogenesis of Alzheimer’s dis-
ease (AD). These characteristic AD lesions can be quanti-
fied in vivo using examination of cerebrospinal fluid 
(CSF) and positron emission tomography with  18 F-fluo-
rodeoxyglucose (FDG-PET)  [1–4] .
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 Abstract 
 Aims: In this study, we aimed to compare cerebrospinal fluid 
(CSF) levels of total tau (t-tau), phosphorylated tau (p-tau 181 ) 
and positron emission tomography with  18 F-fluorodeoxy-
glucose (FDG-PET) in the differential diagnosis of Alzhei-
mer’s disease (AD) under clinical conditions.  Method: In a 
cross-sectional, blinded, single-center study, we examined a 
sample of 75 unselected memory clinic patients with clinical 
diagnoses of dementia of Alzheimer type (DAT; n = 24), am-
nestic mild cognitive impairment (MCI; n = 16), other demen-
tias (n = 13) and nondemented controls (n = 22). Discrimina-
tive accuracy, sensitivity and specificity were calculated and 
compared using ROC analyses.  Results: p-tau 181 and FDG-
PET were comparable in separating DAT from controls (sen-
sitivity: 67 vs. 79%; specificity: 91% for both) and patients 
with other dementias (sensitivity: 71 vs. 79%; specificity: 
100% for both). The sensitivity of p-tau 181 in differentiating 
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 Numerous studies have consistently shown that CSF 
levels of total tau (t-tau) and phosphorylated tau (p-tau) 
proteins are significantly elevated in patients with AD 
compared to healthy elderly controls  [4] . A meta-analysis 
of over 30 studies indicated that both CSF biomarkers 
provided similar values of sensitivity and specificity (80 
and 90%, respectively) in the discrimination of AD ver-
sus healthy aging  [4] . Unlike t-tau, a marker of neuronal 
damage, p-tau specifically reflects tau hyperphosphory-
lation and, likely, the formation of tangles in AD. Accord-
ingly, p-tau but not t-tau levels were found to be useful in 
discriminating between dementia of Alzheimer type 
(DAT) and other non-AD dementias  [5–7] . Reduced CSF 
concentrations of amyloid beta peptides (A  42 and A  40 ) 
have also been used for differential classification of pa-
tients with AD, in most studies in combination with CSF 
tau proteins  [8–10] .
 Like CSF examination, FDG-PET has been widely ap-
plied to assist the diagnosis of AD  [11] . A reduced glucose 
metabolism in the posterior cingulate and parietotempo-
ral association cortices with sparing of the primary sen-
sorimotor areas and cerebellum is a well-established fea-
ture of DAT  [12, 13] . Both visual reading and quantitative 
diagnostic approaches provide a similar sensitivity of 85–
95% and specificity of 80–90% in differentiating probable 
AD from healthy aging  [14–16] . Furthermore, FDG-PET 
was shown to possess a significant diagnostic potential in 
differentiating DAT from dementias of other causes such 
as dementia with Lewy bodies, frontotemporal, and vas-
cular dementia  [17–20] .
 The relatively high accuracy of the PET-derived hypo-
metabolic pattern and abnormal levels of CSF proteins in 
discriminating manifest and even incipient AD  [21, 22] 
has been reflected in recently proposed guidelines on AD, 
where both biomarkers were recommended as supportive 
but obligate diagnostic features  [23] . For the use of bio-
markers in routine diagnostic algorithms and differential 
diagnosis, however, the knowledge of the comparative di-
agnostic accuracy of different single markers is manda-
tory  [24, 25] . So far, these biomarkers – of which one is 
costly but less invasive (FDG-PET), while the others are 
low priced but more invasive (CSF tau levels) – have not 
been compared regarding their discrimination proper-
ties. The objective of the present study was, therefore, to 
estimate the diagnostic accuracy of CSF t-tau, p-tau and 
FDG-PET in an unselected sample of patients with clini-
cally diagnosed DAT, amnestic mild cognitive impair-
ment (MCI) and other dementia disorders, and in nonde-
mented controls.
 Subjects and Methods 
 Subjects 
 The total sample (n = 75) consisted of subjects consecutively 
recruited from our memory clinic in the years 2001–2003. Most 
subjects had been referred to our clinic by general practitioners. 
The protocol including all assessments was part of the established 
clinical routine and accepted by the local ethics committee. All 
participants gave their written informed consent after the proce-
dures had been fully explained. 
 Assessment 
 All subjects underwent interview, clinical psychiatric and 
neurological examinations, lumbar puncture, cranial magnetic 
resonance imaging (MRI), FDG-PET and laboratory tests in-
cluding vitamin B 12 , folate and thyroid hormone status. Neuro-
psychological assessment consisted of the Mini-Mental State Ex-
amination (MMSE) and delayed verbal recall test (DVRT) as part 
of the German version of the CERAD (Consortium to Establish 
a Registry for Alzheimer’s Disease) battery  [26] . The costs of the 
diagnostics were covered by mandatory public health insurance. 
 On the basis of the clinical assessments and conventional cra-
nial MRI scans, the following diagnostic categories were formed: 
(1) patients with probable AD, or DAT, (n = 24) according to 
NINCDS-ADRDA criteria  [27] ; (2) patients with amnestic MCI
(n = 16) according to established criteria by Petersen  [28] ; (3) pa-
tients with other (non-AD) dementias (OD; n = 13) including vas-
cular dementia according to NINDS-AIREN criteria  [29] (n = 6), 
frontotemporal dementia according to Lund-Manchester criteria 
 [30] (n = 2) and other dementias (n = 5), and (4) a nondemented 
control group (NOND; n = 22) that consisted of nondemented 
subjects with a psychiatric or neurological disorder (depression: 
n = 5; Parkinson’s disease: n = 1), or healthy subjects complaining 
of memory deficits not verified by informants and not confirmed 
by neuropsychological tests who had a normal MRI finding on 
visual inspection and no clinical signs of dementia (n = 16). Clin-
ical diagnoses were made without knowledge of the CSF tau pro-
tein levels and FDG-PET findings at the time of initial assess-
ment. 
 CSF Analyses 
 CSF samples were obtained by a standard lumbar puncture 
procedure and immediately frozen at –20   °   C in polypropylene 
tubes until examination. All samples were analyzed within 3 
weeks after lumbar puncture. CSF tau protein levels were de-
termined by 2 sandwich ELISA: tau protein phosphorylated at 
threonine 181 (p-tau 181 ) was determined using the Innogenetics 
INNOTEST Phospho-Tau(181) kit, and t-tau by the INNOTEST-
hTau-Ag kit (Innogenetics, Gent, Belgium)  [31, 32] . For p-tau181 
and t-tau, the limits of detection were 15.6 ng/l and 60.0 ng/l, re-
spectively. The standard ranges were 15.6–500 ng/l for p-tau181, 
and 60.0–1,200 ng/l for t-tau, and the interassay reproducibility 
(coefficient of variation) of quality control samples was below 
10%. At the time this study was conducted, assays for A  were not 
available at out institute, thus their levels could not be deter-
mined.
 FDG-PET Data Acquisition and Analysis 
 Data acqusition has been reported in detail elsewhere [33]. 
Briefly, PET data were acquired under standard resting condi-
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tions using a Siemens ECAT EXACT scanner (CTI, Knoxville, 
Tenn., USA) in 3-D mode. The PET camera has an axial field of 
view of 16.2 cm and axial resolution of approximately 6.0 mm full 
width at half maximum. Thirty minutes after injection of FDG, a 
sequence of three 5-min frames was started and later combined 
into a single frame. After correction for attenuation, scatter and 
dead time, images were reconstructed by filtered back projection 
using a 4-mm Hamming filter. 
 The PET scans were processed using Neurostat software (Uni-
versity of Washington; http://www.rad.washington.edu/research/
Research/groups/nbl/neurostat-3d-ssp)  [12] . After image realign-
ment and spatial normalization, gray matter activities were ex-
tracted to predefined surface pixels using a 3-D stereotactic sur-
face projection (3D-SSP) technique. This technique minimizes 
residual anatomic variances across subjects and partial volume 
effects  [12] . Thereafter, each individual dataset was compared on 
a pixel-by-pixel basis with a normative reference database, result-
ing in parametric Z score images  [34] . The AD-typical finding 
was defined as significant decrease (Z score  !  –2) in FDG uptake 
in at least 1 of the brain regions that were shown to be typically 
involved in early AD (posterior cingulate, lateral temporal, pari-
etal regions)  [12, 13] . This routine has been extensively evaluated 
in various disorders and has shown high external validity in both 
mono-  [17, 35] and multicenter  [20] studies. Based on this analysis 
and inspection of transversal FDG-PET image slices (TomoMag-
ine software, http://tomomagine.de/index2.htm), the findings 
were finally rated as AD-typical or not AD-typical by 2 experi-
enced physicians in nuclear medicine blinded to all other test re-
sults, including clinical diagnoses and CSF tau proteins. Dis-
agreements were resolved by consensus. In an earlier study by our 
group using the identical rating protocol  [34] , the interobserver 
agreement was 94%.
 Statistical Analysis 
 Descriptive statistics are shown as mean values, ranges and 
SD. For p-tau 181 and t-tau levels, group median and interquartile 
range (25th–75th percentile) are presented because the distribu-
tions differed statistically significantly from normal as deter-
mined by the D’Agostino-Pearson test (p  ! 0.01)  [36] . Group dif-
ferences in categorical data were analyzed by   2 tests; differences 
among all groups regarding continuous variables were assessed 
by nonparametric Kruskal-Wallis tests followed by Mann-Whit-
ney U tests for single comparisons. Correlations were analyzed by 
Spearman’s rank correlation coefficients.
 To assess the predictive properties of FDG-PET, CSF p-tau 181 
and t-tau, receiver operating characteristic (ROC) curve analysis 
was employed (MedCalc 9.3.6., 2007). The area under the ROC 
curve (AUC) with corresponding 95% confidence intervals (95% 
CI) was estimated; further, sensitivity, specificity, positive predic-
tive value, negative predictive value and accuracy (percentage of 
correctly classified subjects) were calculated. Using clinical diag-
noses as the criterion standard, the following ROC analyses were 
performed: comparison of patients with (1) DAT versus NOND, 
(2) DAT versus OD, (3) DAT versus MCI and (4) MCI versus 
NOND. Dichotomized binary FDG-PET findings, CSF t-tau and 
p-tau 181 levels were used as predictor variables. Additionally, age 
was used as the control predictor variable. Unbiased estimations 
of the AUC can be calculated in the same way for binary and con-
tinuously valued diagnostic tests  [37] .
 Finally, the correspondence between CSF tau protein levels 
and FDG-PET findings was analyzed by ROC curves and group 
comparisons (Mann-Whitney U tests and   2 tests) in patients 
with or without AD-typical FDG-PET findings, irrespective of 
their clinical diagnoses. The level of statistical significance was 
set at a two-tailed   of 0.05. In case of multiple comparisons, Bon-
ferroni adjustment was applied. 
 Results 
 Table 1 shows the characteristics of the 75 patients re-
cruited for the study.  Table 2 summarizes the results of 
overall group differences and Bonferroni-corrected sin-
gle group comparisons.
 Only minor differences emerged with respect to gen-
der; age was not significantly different between the 
groups. Significant gender differences in CSF tau levels or 
the frequency of AD-typical FDG-PET findings were 
found neither between the 4 subgroups nor in the total 
group (p  1 0.10). In the total sample, no significant cor-
relation between age and CSF levels of t-tau (r s = 0.21;
Table 1.  Characteristics of study sample
Diagnostic
group
Num-
ber
Female
%
Age, years MMSE score DVRT score AD-typical
PET, %
CSF level1, ng/l
p-tau181 t-tau 
NOND 22 41 (9) 61.8813.3 (43–82) 27.383.1 (25–30) 6.882.6 (1–10) 9 (2) 34 (16–46) 341 (176–435)
MCI 16 44 (7) 68.687.9 (51–83) 26.182.2 (22–30) 3.181.8 (1–7) 44 (7) 62 (44–87) 336 (102–456)
DAT 24 79 (19) 70.389.5 (51–89) 18.785.8 (4–27) 2.082.8 (0–8) 79 (19) 74 (48–105) 452 (248–701)
OD 13 39 (5) 68.1810.0 (51–80) 22.286.5 (6–30) 3.383.4 (0–9) 0 (0) 16 (7–35) 240 (44–425)
Total 75 53 (40) 67.0810.9 (43–89) 23.48 5.9 (4–30) 3.883.2 (0–10) 37 (28) 48 (17–76) 349 (181–459)
Va lues are means 8 SD unless specified otherwise. Figures in parentheses denote numbers or ranges unless specified otherwise.
1 Medians with 25th–75th percentiles in parentheses.
 Yakushev et al. Dement Geriatr Cogn Disord 2010;30:245–253248
d.f. = 73; p = 0.07) or p-tau 181 (r s = 0.16; d.f. = 73; p = 0.18) 
was noted.
 Global cognitive function as indicated by the MMSE 
score was significantly more impaired in DAT patients 
than in NOND and MCI subjects; patients with OD dif-
fered significantly from NOND but not from MCI or 
DAT patients regarding their MMSE scores. DVRT per-
formance was significantly better in NOND subjects 
than in all other groups (MCI, DAT, OD) and was better 
in MCI than in DAT patients. 
 The t-tau protein levels differed significantly only be-
tween the groups of DAT and OD patients; p-tau 181 levels 
were significantly higher in MCI and DAT patients com-
pared to NOND and patients with OD. AD-typical FDG-
PET findings were noted more frequently in patients with 
DAT than in the NOND and OD groups. No significant 
difference in the frequency of AD-typical FDG-PET 
findings was found between MCI and DAT patients after 
Bonferroni correction (uncorrected p = 0.021) ( table 2 ). 
Table 2.  Group differences (n = 75)
Global test Single comparisons*
Gender (% female) 2 = 9.5; d.f. = 3; p = 0.023a NOND<DATa
Age 2 = 5.3; d.f. = 3; p = 0.151b –c
MMSE 2 = 37.3; d.f. = 3; p < 0.0001b NOND>DAT, OD; MCI>DATc
DVRT 2 = 28.8; d.f. = 3; p < 0.0001b NOND>MCI, DAT, OD; MCI>DATc
AD-typical PET 2 = 33.5; d.f. = 3; p < 0.0001a NOND, OD<DATa
p-tau181 2 = 28.3; d.f. = 3; p < 0.0001b NOND, OD<MCI, DATc
t-tau 2 = 7.2; d.f. = 3; p = 0.065b OD<DATc
* p < 0.05/6 (= 0.0083) after Bonferroni correction.
a 2 test. b Kruskal-Wallis test. c Mann-Whitney U test.
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 Fig. 1. ROC curves for discrimination of patients with DAT and 
non-AD dementias. 
 Fig.  2. ROC curves for discrimination of MCI patients from 
NOND individuals. 
 CSF Tau Proteins and FDG-PET in AD Dement Geriatr Cogn Disord 2010;30:245–253 249
 Table 3 shows the results of the ROC analyses of 4 pa-
rameters (FDG-PET, p-tau 181 , t-tau and age) for the rele-
vant group comparisons (DAT, MCI, OD and NOND).
 The performance of FDG-PET findings and CSF p-
tau 181 levels to separate DAT patients from patients with 
OD is illustrated in  figure 1 ( table 2 ).
 The accuracy of the biomarkers for separating MCI 
patients from NOND individuals was, in general, rela-
tively low. However, p-tau 181 levels performed most accu-
rately when compared to FDG-PET findings, t-tau levels 
and age ( fig. 2 ). The sensitivity of p-tau 181 to differentiate 
MCI from NOND individuals was significantly superior 
to that of FDG-PET (p = 0.02), whereas the specificity
(p = 0.42), accuracy (p = 0.59) and AUC ( table 3 ) of both 
markers were similar (p = 0.28). Compared to t-tau, the 
AUC for identifying MCI patients was significantly larg-
er for p-tau 181 (p = 0.001), but not for FDG-PET patterns 
(p = 0.11).
 The association of AD-typical FDG-PET patterns with 
CSF tau protein levels is shown in  figure 3 . p-Tau 181 and 
t-tau levels were significantly higher in subjects with AD-
typical FDG-PET findings than in patients without such 
findings (Mann-Whitney U test, p-tau 181 : Z = –5.088, p  ! 
0.0001; Mann-Whitney U test, t-tau: Z = –3.012, p = 0.003). 
A cutoff value of p-tau 181 of  1 65 ng/l was found to separate 
patients with and without AD-typical FDG-PET (AUC = 
0.85; 95% CI: 0.75–0.92; sensitivity: 71%; specificity: 89%), 
whereas CSF t-tau concentrations of  1 520 ng/l were iden-
tified as an optimal cutoff value (AUC = 0.71; 95% CI: 
0.59–0.81; sensitivity: 39%; specificity: 92%). When the 
sensitivity was set at 85%, specificities of 70% (cutoff: 45 
ng/l) for p-tau 181 , and of 40% (cutoff: 220 ng/l) for t-tau 
concentrations were found. The AUC for t-tau and p-
tau 181 were significantly different (p = 0.003). Twenty of 28 
patients (71%) with AD-typical FDG-PET findings had p-
tau 181 levels of  1 65 ng/l, compared to 5 of 47 patients (11%) 
without such findings (  2 = 26.5; d.f. = 1; p  ! 0.00001).
Table 3.  Results of ROC curve analyses
(1) (2) (3) (4)
Comparison: DAT vs. NOND DAT vs. OD DAT vs. MCI MCI vs. NOND
Number 46 (24/22) 37 (24/13) 40 (24/16) 38 (16/22)
AUC FDG-PET 0.85a, b (0.71–0.94) 0.90a, b (0.75–0.97) 0.68 (0.51–0.82) 0.67 (0.50–0.82)
p-tau181 0.82a, b (0.68–0.92) 0.91a, b (0.77–0.98) 0.59 (0.42–0.74) 0.77b (0.61–0.89)
t-tau 0.68 (0.53–0.81) 0.73a (0.56–0.87) 0.61 (0.44–0.76) 0.49 (0.32–0.66)
age 0.68 (0.53–0.81) 0.54 (0.37–0.70) 0.57 (0.41–0.73) 0.65 (0.48–0.80)
Optimal cutoff values FDG-PET AD-typical AD-typical AD-typical AD-typical
p-tau181 >65 ng/l >65 ng/l >50 ng/l
t-tau >520 ng/l >440 ng/l
age >67 years
SENS/SPEC FDG-PET 79/91 79b/100 79/56 44/91
p-tau181 67/91 71/100 75c/82
t-tau 46/96 54/92
age 67/68
PPV/NPV FDG-PET 91/80 100/72 73/64 78/69
p-tau181 89/71 100/65 75/82
t-tau 92/63 93/52
age 70/65
Accuracy FDG-PET 85% (39/46) 87% (32/37) 70% (28/40) 71% (27/38)
p-tau181 79% (36/46) 78% (29/37) 79% (30/38)
t-tau 70% (33/46) 67% (25/37)
age 68% (31/46)
S ENS = Sensitivity; SPEC = specificity; PPV = positive predictive value; NPV = negative predictive value. Comparison of AUC and 
specificity/sensitivity: a p < 0.05 versus age; b p < 0.05 versus t-tau; c p < 0.05 versus FDG-PET; cutoff values and parameters of predic-
tive power were only shown when AUC were significantly different from 0.50, i.e. the 95% CI did not include 0.50.
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 Discussion 
 The main findings of the present study were that FDG-
PET and CSF p-tau 181 levels performed well in differenti-
ating DAT patients from NOND controls and patients 
with non-AD dementias, whereas CSF p-tau 181 was some-
what superior in the sensitive detection of patients with 
amnestic MCI who are considered to be at high risk for 
DAT. The findings were not related to age and gender, 
confirming that CSF p-tau 181 is a clinically valuable bio-
marker of early AD  [6, 7] . Finally, and as expected, the 
accuracy of FDG-PET and CSF p-tau 181 levels was sig-
nificantly superior to t-tau measures in all analyses. 
 A strength of the present study is its maximal proxim-
ity to routine clinical practice. To assess the utility of any 
biomarker, detailed elaboration of the setting in which 
the biomarker is efficient is highly important  [38] . As a 
matter of fact, most PET and CSF studies are performed 
at academic centers with participating subjects being 
highly selected  [39, 40] . Yet, as a likely application of any 
biomarker is to complement clinical diagnosis, one needs 
to know if or to what extent the existing data on the
diagnostic accuracy of a biomarker might generalize to 
patients presenting to a clinician. Here, we studied a rel-
atively large unselected sample representative of a uni-
versity memory clinic. The patients and controls were 
somewhat younger than patients with AD in the commu-
nity and than AD subjects who generally participate in 
clinical trials. Other aspects such as education and co-
morbidity, although important, were not addressed in
the present study. Nonetheless, our approach to study a 
mixed collective of subjects with a broad variety of pos-
sible causes, relatively low age and partially preserved 
cognitive performance in all groups provides valuable in-
sights into the diagnostic performance of the biomarkers, 
i.e. CSF tau proteins and FDG-PET, evaluated under clin-
ical conditions.
 In the literature, we found no study that had examined 
CSF p-tau levels in unselected patient collectives. As to 
FDG-PET, Scheltens et al.  [41] and Jagust et al.  [42] ap-
plied this neuroimaging tool to relatively unselected 
community samples; the issue of diagnostic accuracy 
was, however, not addressed in those studies. In view of 
that, the findings of the present study are of special inter-
est. Overall, the accuracy of FDG-PET in discriminating 
DAT patients from both controls and OD patients was 
around 85%, thus well within the range typically report-
ed in the literature (80–90%). Similarly, levels of CSF p-
tau appeared to identify subjects with DAT with an ac-
curacy of roughly 80%, also confirming findings from 
previous CSF studies (see Introduction). Of note, both 
biomarkers offered a high specificity of 90–100%. Thus, 
our data indicate that FDG-PET and CSF p-tau are able 
to detect DAT in heterogeneous and unselected samples 
with a high accuracy. 
 The clinical manifestation of AD begins insidiously, 
and now there is broad agreement that individuals with 
the amnestic subtype of MCI represent early clinical 
manifestations of AD with a high risk for transition to 
dementia within a few years  [28] . In our study, the accu-
racy of FDG-PET in differentiating this clinical entity 
from nondemented controls was roughly 70% with a poor 
sensitivity (44%) but a high specificity (91%). While most 
of the (cross-sectional) studies used a quantitative region-
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of-interest analysis, a few have examined the discrimina-
tive accuracy of the hypometabolic pattern in visual read-
ings. Those studies reported rather variable results, with 
figures for accuracy ranging from 20 to 70%  [43–45] . No-
tably, a better discrimination could be reached in studies 
that applied 3D-SSP  [43, 45] . Thus, although the accuracy 
of FDG-PET in differentiating MCI from nondemented 
controls in the present study was relatively poor, its fig-
ures were still within the ‘optimistic range’ known from 
the literature. Indeed, metabolic deficits in MCI are, in 
general, milder and more variable than those found in 
DAT and are thought to agree with the heterogeneity of 
outcomes as well as with variations in the patterns of cog-
nitive and behavioral alterations in individual subjects 
 [46] .
 As to CSF markers in MCI, we found no study that had 
examined the discriminative performance of tau levels 
cross-sectionally. In the present study, CSF p-tau tended 
to perform better than FDG-PET in differentiating MCI 
from controls. Keeping in mind the above point about a 
relatively poor sensitivity of the AD-typical PET findings 
in MCI, this finding has rather been expected. In contrast 
to FDG-PET, CSF p-tau levels are not related to a particu-
lar brain region and may therefore be more robust in de-
tecting early AD. Yet, as t-tau and p-tau levels stay rela-
tively stable over significant periods of time despite the 
clinical progression of the disease  [22] , they do not seem 
to be superior to FDG-PET at the stage of DAT.
 According to a recently proposed concept, both FDG-
PET and p-tau levels reflect the same process, i.e. AD-
specific neurodegeneration  [47] . Our earlier as well the 
present data support this view. Previously, we have dis-
closed a strong relationship between elevated p-tau levels 
and AD-typical patterns of cerebral glucose metabolism 
in patients with amnestic MCI  [34] . In line with this, a 
recent study reported a significant correlation between 
CSF p-tau181, a marker of neurofibrillary pathology  [1] , 
and relative metabolic indices (as measured by FDG-
PET) in the entorhinal/hippocampal and AD-typical re-
gions in patients with probable AD  [48] . A close neuro-
biological proximity of these two biomarkers has further-
more been highlighted in the present study, in which 71% 
of subjects with AD-typical FDG-PET findings, irrespec-
tive of their diagnostic classification, had pathological p-
tau 181 levels. 
 There are several limitations to the present study. First, 
a follow-up examination was not available for many MCI 
patients (n = 7), precluding meaningful statistical analy-
ses at a subgroup level. Although MCI is characterized by 
a high conversion rate to DAT, some individuals remain 
stable, revert, or develop other dementias  [28] . Second, 
for technical reasons (unavailability of appropriate as-
says), we could not examine CSF A  levels. Although, in 
general, this parameter seems less specific for AD pathol-
ogy as p-tau  [49, 50] , several studies demonstrated that a 
combination of tau proteins and A  or their ratio might 
have better diagnostic properties for detecting AD than 
each parameter on its own  [22, 51] . Finally, there are 
many potential ways to analyze PET data. In the present 
study, we inspected 3D-SSP and transaxial images. Be-
cause of theoretical advantages  [12] and a straightforward 
way of data presentation, the technique of 3D-SSP has 
been widely used in many clinics, in both single- and 
multicenter trials  [20] . From our experience and the lit-
erature, at present, it is likely to be the most popular soft-
ware for the visual interpretation of FDG-PET images in 
clinical practice. Nevertheless, there are several other 
software packages available that display images topo-
graphically, generate statistical maps and may provide 
similar, or in combination with 3D-SSP even superior, 
results.
 In conclusion, our data suggest that under clinical 
conditions, FDG-PET and CSF p-tau 181 levels perform 
very accurately in differentiating DAT patients from non-
demented controls and patients with non-AD dementias, 
whereas CSF p-tau 181 might be somewhat superior in the 
sensitive detection of patients with amnestic MCI.
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